NasdaqCM - Nasdaq Real Time Price USD

CASI Pharmaceuticals, Inc. (CASI)

1.8400
+0.0309
+(1.71%)
At close: June 13 at 4:00:01 PM EDT
1.7601
-0.08
(-4.34%)
After hours: June 13 at 7:55:16 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
31,368
28,537
33,879
43,107
30,168
Cost of Revenue
18,409
17,391
13,827
15,827
12,557
Gross Profit
12,959
11,146
20,052
27,280
17,611
Operating Expense
53,185
50,358
45,332
53,771
52,828
Operating Income
-40,226
-39,212
-25,280
-26,491
-35,217
Net Non Operating Interest Income Expense
-391
-332
614
127
321
Other Income Expense
1,326
1,475
-1,626
-11,067
-946
Pretax Income
-39,291
-38,069
-26,292
-37,431
-35,842
Tax Provision
0
0
-81
1,980
0
Earnings from Equity Interest Net of Tax
-1,189
-1,189
-48
-846
0
Net Income Common Stockholders
-40,480
-39,258
-26,960
-41,014
-36,654
Diluted NI Available to Com Stockholders
-40,480
-39,258
-26,960
-41,014
-36,654
Basic EPS
-2.54
-2.56
-2.02
-3.01
-2.69
Diluted EPS
-2.54
-2.56
-2.02
-3.01
-2.69
Basic Average Shares
15,867.9280
15,340.2770
13,360.1850
13,647.4550
13,610.4410
Diluted Average Shares
15,867.9280
15,340.2770
13,360.1850
13,647.4550
13,610.4410
Total Operating Income as Reported
-40,546
-39,621
-25,080
-34,032
-41,516
Total Expenses
71,594
67,749
59,159
69,598
65,385
Net Income from Continuing & Discontinued Operation
-40,480
-39,258
-26,938
-41,014
-36,654
Normalized Income
-41,758
-40,545
-24,555.3631
-28,687
-35,150
Interest Income
485
539
629
189
321
Interest Expense
876
871
15
62
--
Net Interest Income
-391
-332
614
127
321
EBIT
-38,415
-37,198
-26,277
-37,369
-35,217
EBITDA
-38,415
-34,867
-22,536
-34,947
-33,402
Reconciled Cost of Revenue
18,409
17,391
13,827
15,827
12,557
Reconciled Depreciation
--
2,331
3,741
2,422
1,815
Net Income from Continuing Operation Net Minority Interest
-40,480
-39,258
-26,938
-41,014
-36,654
Total Unusual Items Excluding Goodwill
1,278
1,287
-2,390
-16,436
-1,504
Total Unusual Items
1,278
1,287
-2,390
-16,436
-1,504
Normalized EBITDA
-39,693
-36,154
-20,146
-18,511
-31,898
Tax Rate for Calcs
0
0
0
0.0003
0
Tax Effect of Unusual Items
0
0
-7.3631
-4,109
0
12/31/2021 - 6/12/1996

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CSBR Champions Oncology, Inc.
7.66
+3.58%
 
PALI Palisade Bio, Inc.
0.6401
-7.23%
 
RADX Radiopharm Theranostics Limited
5.05
-5.25%
 
SLGL Sol-Gel Technologies Ltd.
7.52
+8.99%
 
CYCC Cyclacel Pharmaceuticals, Inc.
0.4121
+14.79%
 
MGNX MacroGenics, Inc.
1.5200
-1.94%
 
KAPA Kairos Pharma, Ltd.
0.5200
-8.77%
 
JBIO Jade Biosciences, Inc.
6.76
-2.59%
 
ALZN Alzamend Neuro, Inc.
3.2400
+1.57%
 
EQ Equillium, Inc.
0.3470
-10.22%